Objectives <p>To explore the effect of ligustrazine phosphate tablets combined with cerebroside carnosine on neurological function and serum inflammatory factors among patients with ischemic cerebrovascular disease.</p> Methods <p>This was a quasi-experimental study. From March 2019 to February 2022, 126 patients were non-randomly divided into control (<i>n</i> = 63) and intervention (<i>n</i> = 63) groups. The control group received routine treatment such as encephaloside and carnosine, while the intervention group was treated with ligustrazine phosphate tablets and brain glycoside carnosine for 2&#xa0;weeks. Serum S-100β protein, nerve growth factor (NGF), inflammatory factors [tumor necrosis factor-α (TNF-α) and C-reactive protein (CRP)], National Institutes of Health Stroke scale (NIHSS) and and Activities of Daily Living (ADL) scale were assessed before and after the intervention.</p> Results <p>After treatment, the level of S-100β in the intervention group was lower, and the level of NGF was significantly higher than in the control group. The levels of TNF-α and CRP in the intervention group were reduced. The NIHSS score of the intervention group was lower, and the ADL score was significantly higher than that of the control group.</p> Conclusions <p>The combination of ligustrazine phosphate tablets with cerebroside carnosine can improve neurological function, alleviate inflammation, and enhance the quality of life, worthy of clinical promotion.</p>